Get access

Disease modifying immunosuppressant drugs for juvenile-onset systemic lupus erythematosus

  • Protocol
  • Intervention

Authors

  • Jean V Craig,

    Corresponding author
    1. School of Medicine, Health Policy and Practice, NIHR Research Design Service for the East of England (Norfolk and Suffolk), Norwich, UK
    • Jean V Craig, NIHR Research Design Service for the East of England (Norfolk and Suffolk), School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, NR4 7TJ, UK. Jean.Craig@uea.ac.uk.

    Search for more papers by this author
  • Clare E Pain,

    1. Alderhey Children's Hospital NHS Foundation Trust, Rheumatology Department F3, Liverpool, Merseyside, UK
    Search for more papers by this author
  • Michael William Beresford

    1. University of Liverpool, Institute of Child Health, Liverpool, Merseyside, UK
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To summarise the evidence from randomised controlled trials for the effectiveness and safety of DMARDs in the treatment of juvenile-onset systemic lupus erythematosus, specifically:

  1. To quantify the effects of DMARDs on disease activity, health related quality of life, risk of permanent organ damage and steroid dose.

  2. To determine what serious adverse events are associated with DMARDs (using evidence from randomised controlled trials only).  

  3. To report on the tolerability of DMARDs.

    

Get access to the full text of this article